Browse the evidence

High-fat diet feeding induces an early and sustained infiltration of pro-inflammatory macrophages (CD11c+CD11b+F4/80+) into skeletal muscle, which correlates with insulin resistance and is dependent on the chemokine CCL2.

In the context of obesity and high-fat diets, skeletal muscle undergoes a specific immune response where pro-inflammatory macrophages infiltrate the tissue, driven by the chemokine CCL2. This infiltration is directly linked to the development of insulin resistance. While this is a mechanistic finding primarily from mouse models, it suggests that chronic high-fat intake triggers a local immune response in muscle that impairs glucose disposal, independent of simple caloric excess.

Oleic acid stimulates complete fatty acid oxidation in skeletal muscle by activating the cAMP/PKA pathway, which phosphorylates and activates SIRT1, leading to PGC1α deacetylation and increased expression of fatty acid oxidation genes.

Consuming oleic acid (found in olive oil and other monounsaturated fats) may actively signal your muscles to burn fat more efficiently by activating specific cellular pathways (SIRT1/PGC1α). This is distinct from saturated fats, which do not trigger this specific oxidation-promoting signal. Prioritizing monounsaturated fats may support metabolic flexibility.

Oral estrogen therapy in postmenopausal women causes adverse body composition changes (increased fat mass, decreased lean body mass) compared to transdermal estrogen, mediated by a first-pass hepatic suppression of lipid oxidation and IGF-I levels.

If you are using estrogen replacement therapy, the method of delivery matters for your body shape. Oral estrogen (pills) can lead to increased body fat and loss of muscle mass in postmenopausal women, likely due to how the liver processes the hormone. Transdermal estrogen (patches) avoids these specific metabolic shifts. Discuss route-specific metabolic impacts with your provider if body composition is a concern.

Reduced insulin/IGF-1 signaling (IIS) extends lifespan across species by conserving specific biological processes—specifically, the down-regulation of protein biosynthesis and the up-regulation of cellular detoxification (including GSTs)—rather than by conserving specific orthologous genes.

Focus on maintaining healthy insulin sensitivity and cellular detoxification pathways rather than searching for a single 'magic bullet' gene. Interventions that reduce insulin signaling (like caloric restriction or specific pharmacological agents) may promote longevity by triggering these conserved process-level responses (reduced protein synthesis, increased detoxification) rather than by acting on a single specific gene target.

Bariatric surgery-induced weight loss in morbidly obese patients significantly improves insulin sensitivity, endothelial function, and specific inflammatory markers (CRP, sialic acid, E-selectin, P-selectin, vWF, PAI-1), although proinflammatory cytokines (TNF-alpha, IL-6) may remain elevated.

For morbidly obese individuals, bariatric surgery can significantly improve insulin sensitivity and endothelial function within months, reducing cardiovascular risk. However, not all inflammatory markers (like TNF-alpha and IL-6) may normalize, suggesting that metabolic stress or residual adiposity might sustain some inflammatory pathways. This highlights the importance of addressing insulin resistance specifically.

Self-administration of polydrug androgenic-anabolic steroid (AAS) regimens for 8-14 weeks significantly decreases HDL-C, HDL2-C, HDL3-C, and Apo-A1, while increasing Apo-B, creating a highly atherogenic lipid profile.

Using multiple anabolic steroids at high doses significantly worsens your cholesterol profile by lowering 'good' cholesterol (HDL) and raising 'bad' markers (Apo-B). This effect is not subtle; it creates a high-risk state for heart disease that does not immediately resolve after you stop using the drugs, especially if you use them for longer periods (14 weeks vs 8 weeks).

Disruption of the skeletal muscle molecular clock (specifically Bmal1 loss) causes severe muscle pathology, including reduced force production, altered sarcomeric structure, and impaired mitochondrial respiration.

Maintain consistent sleep and feeding schedules to keep your muscle clocks synchronized. Disrupted rhythms (like shift work or erratic eating) may impair muscle strength and mitochondrial health, even if you exercise. Prioritize regularity in daily habits to support muscle maintenance.

Inhibition of the Insulin/IGF-1 Signaling (IIS) pathway extends lifespan in multiple species by enhancing mitochondrial function, biogenesis, and mitophagy.

Genetic variants that naturally result in lower IGF-1 levels are associated with human longevity. While not a direct prescription, this suggests that the hormonal environment of reduced growth signaling may be protective against aging, distinct from the muscle-building goals of high IGF-1 in youth.

Insulin regulates free fatty acid (FFA) appearance in plasma primarily by inhibiting lipolysis, while maintaining a constant absolute rate of primary intra-adipocyte FFA reesterification.

Insulin controls blood fat levels mostly by stopping fat cells from releasing fat, not by burning it. This happens at relatively low insulin levels. High insulin levels are needed to significantly change how much fat your muscles burn. For weight management, keeping insulin levels stable helps prevent fat release from adipose tissue.

Metformin is not recommended for treating NAFLD or NASH in humans despite improving insulin sensitivity in animal models.

Do not rely on metformin to treat your fatty liver. While it helps control blood sugar in diabetes, studies show it does not improve liver health in people with NAFLD or NASH. Focus on weight loss and dietary changes instead.

Genetic inactivation of brain fatty acid synthase (FAS) in the hypothalamus causes hypophagia and increased physical activity by impairing PPARα signaling, which can be reversed by administering a PPARα agonist.

This research identifies a specific brain mechanism where the enzyme FAS helps regulate appetite and activity by activating PPARα. While this doesn't suggest a direct supplement or drug for humans yet, it highlights that brain metabolism of fats plays a crucial role in energy balance, distinct from peripheral fat storage.

Reduced insulin/insulin-like growth factor (IIS) signaling extends lifespan and healthspan in model organisms but is associated with reduced skeletal muscle mass and function in aging humans.

Genetic studies show that dampening IGF-1 signaling can extend lifespan in mice, even if it reduces muscle size. However, in humans, low IGF-1 is linked to sarcopenia and frailty. The key takeaway is not to suppress IGF-1 artificially, but to understand that the pathways driving muscle growth (like mTOR) are the same ones that, when chronically overactive, might accelerate aging. The goal is balance: maintaining muscle through exercise and adequate protein without necessarily maximizing anabolic signaling to the point of potential cellular stress.

Plasma LEAP2 levels increase with higher body mass, obesity, and postprandial states in humans and mice, acting as an endogenous antagonist to acyl-ghrelin to limit food intake and blood glucose elevation.

Your body produces a hormone called LEAP2 that increases when you are overweight or after you eat. This hormone acts as a brake on the 'hunger hormone' (ghrelin) to prevent you from overeating and spiking blood sugar. This is a natural regulatory mechanism. While high LEAP2 is associated with obesity, it also decreases when you lose weight, suggesting your body's hormonal 'brakes' can adjust as your metabolic state changes.

Weight loss induces adipocyte shrinkage and metabolic adaptations that create a persistent biological drive to regain weight by increasing nutrient clearance efficiency and lowering energy expenditure, creating an 'energy gap' that promotes overeating.

Understand that after losing weight, your body biologically fights to regain it by making you hungrier and burning fewer calories. This is not a failure of willpower. Successful long-term maintenance requires acknowledging this persistent biological pressure and likely needs comprehensive, persistent strategies (behavioral, environmental, or pharmaceutical) to counter it, rather than relying on willpower alone.

High doses of fructose (unrealistic for human nutrition) can induce lipogenesis and metabolic syndrome in rodents, but these effects do not extrapolate to moderate human consumption.

Do not rely on high-dose animal studies to judge the safety of your diet. Those studies use doses of fructose that are impossible to consume in a normal human diet. At normal consumption levels, your body handles fructose differently than the stressed animal models.

Increased appetite during a depressive episode is the primary driver of associations between depression and metabolic/inflammatory markers (BMI, metabolic syndrome components, waist circumference, CRP, TNF-α).

If you are depressed and experiencing increased appetite, this is a specific biological subtype ('immuno-metabolic depression') linked to higher inflammation and metabolic risk. It is not just 'overeating' but a symptom. Standard antidepressants may not address this. Discuss with your doctor whether treatments targeting inflammation (like anti-inflammatories or statins, though evidence is mixed) or lifestyle interventions (diet, weight loss) might be beneficial for this specific subtype.

Glucagon receptor signaling regulates hepatic lipid metabolism by stimulating beta-oxidation and inhibiting lipogenesis, thereby reducing hepatic lipid accumulation.

Glucagon plays a crucial role in how your liver handles fat. While high glucagon in diabetes can be problematic, activating glucagon receptors (especially when combined with GLP-1) helps the liver burn fat and reduces liver fat storage. This is why combination therapies are effective for metabolic health.

Glucagon stimulates lipolysis in rodent adipocytes but has no significant lipolytic effect on human adipocytes at physiological concentrations.

Unlike in mice, glucagon does not directly trigger significant fat breakdown in human fat cells at normal levels. Its main job in lipid metabolism is managing fat in the liver, not burning fat from storage cells.

The ApoE E4 isoform is deleterious to longevity, while the E2 isoform is protective, with the E4 allele conferring up to an 8-15 fold increased risk for Alzheimer's disease and premature death from age-related conditions.

If you carry the ApoE E4 allele, your genetic risk for Alzheimer's and cardiovascular disease is significantly higher. This genotype is associated with lower odds of reaching extreme old age. Focus on aggressive management of cardiovascular risk factors (lipids, blood pressure) and cognitive health, as these are the pathways through which E4 impacts longevity.

Pharmacological inhibition of de novo ceramide synthesis using myriocin reduces hepatic steatosis, atherosclerosis, and insulin resistance in diet-induced NAFLD models by normalizing ApoB production and enhancing HDL turnover.

This research suggests that high levels of ceramides, often elevated in fatty liver disease, drive cardiovascular risk by increasing bad cholesterol production (ApoB) and slowing down good cholesterol clearance (HDL). While myriocin is not a consumer supplement, the mechanism implies that dietary strategies reducing saturated fat intake and improving insulin sensitivity may lower ceramide levels, thereby protecting against liver and heart disease.

Interleukin-6 (IL-6) secreted by brown adipose tissue is required for the insulin-sensitizing effects of BAT transplantation, acting as a key 'batokine'.

This finding highlights the complexity of metabolic signaling. While exercise and cold exposure increase IL-6, its source and context determine its effect. BAT-derived IL-6 improves insulin sensitivity, whereas chronic elevation in obesity may contribute to resistance. Focus on activating BAT through cold exposure to harness these beneficial hormonal effects.

Exogenous administration of the weak androgen nandrolone decanoate (ND) to obese postmenopausal women undergoing weight loss increases lean body mass and preferentially reduces subcutaneous abdominal fat, but significantly worsens the lipid profile (increased LDL, decreased HDL).

For obese postmenopausal women, using nandrolone decanoate during weight loss can help preserve or build muscle and reduce subcutaneous belly fat. However, this comes with a significant trade-off: it worsens cholesterol levels (lowering 'good' HDL and raising 'bad' LDL). Given these cardiovascular risks, this treatment is not recommended for this population despite the body composition benefits.

Antiandrogen treatment with spironolactone (SP) in obese postmenopausal women undergoing weight loss results in a smaller loss of subcutaneous abdominal fat compared to placebo, with no significant improvement in visceral fat loss.

Taking spironolactone (75mg daily) during weight loss does not appear to offer any advantage in fat loss or body composition for obese postmenopausal women compared to diet alone. It may even result in less total fat loss.

Obese individuals exhibit a diminished endogenous postprandial Peptide YY (PYY) response compared to lean individuals, despite consuming more calories.

If you are obese, your body may not produce enough PYY after meals to signal fullness effectively, making it harder to stop eating. This is a biological reality, not a lack of willpower. Strategies that support gut health and satiety signaling are important, but recognizing this biological barrier can reduce self-blame and help in seeking appropriate interventions.